RxDoctor Payments Data

Steven Nierenberg, MD

Cardiovascular Disease · Phila, PANPI 1245215136

Payments from drug & device makers

$4,320in general payments, 2019–2025

Across 241 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$867
  • Amgen$529
  • Johnson & Johnson$489
  • Boehringer Ingelheim$440
  • Novartis$388
  • Merck$334
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,308100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,320 in reported general payments places this provider in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$152,522
Medicare patients
432
Services billed
1,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban214$220,365
JardianceEmpagliflozin44$53,612
XareltoRivaroxaban40$38,779
Repatha SureclickEvolocumab20$27,166
EntrestoSacubitril/Valsartan30$23,630
FarxigaDapagliflozin Propanediol20$15,582
Metoprolol Succinate481$10,358
Atorvastatin Calcium645$9,440
Varenicline Tartrate13$7,889
Valsartan79$4,460
Carvedilol293$4,439
Diltiazem 24hr Er (Cd)Diltiazem Hcl100$4,321
Losartan Potassium193$3,322
Amiodarone Hcl58$3,166
Ezetimibe127$2,924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$175$220,365214 claims
Boehringer IngelheimJardiance$440$53,61244 claims
Johnson & JohnsonXarelto$489$38,77940 claims
NovartisEntresto$388$23,63030 claims
AstraZenecaFarxiga$202$15,58220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Phila

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →